James Kihara, who serves as Principal Accounting Officer at Acadia Pharmaceuticals Inc (NASDAQ:ACAD), executed a series of stock sales totaling $41,895. The transactions occurred between March 25 and March 26, 2026, and involved the disposition of 1,942 common shares at prices ranging from $21.47 to $21.7253. Company filings indicate the sales were made to cover withholding taxes and other tax-related obligations.
Those sales directly followed the vesting of restricted stock units earlier in the week. On March 24 and March 25, Kihara received a total of 3,769 shares of common stock upon the vesting of those restricted stock units, according to the disclosure. The sequence of vesting followed by targeted share sales to meet tax liabilities is the sole rationale provided in the filing for the transactions.
At the time of the reported sales, Acadia's shares were trading at $21.47 and the company carried a market capitalization of $3.67 billion. Separately, InvestingPro's analysis is cited indicating that, at current levels, Acadia appears to be trading at a price-to-earnings ratio of 9.4, which InvestingPro characterizes as suggesting the stock may be undervalued. A comprehensive Pro Research Report covering ACAD and more than 1,400 other U.S. equities is noted as available for investors seeking additional analysis.
Beyond the insider transaction, several company developments are referenced in regulatory and market commentary. Acadia announced its recent earnings and revenue results, which are described as pivotal for investors, though no specific figures are provided in the disclosure accompanying the transaction report. Credit and equity research activity is also mentioned: BofA Securities is reported to have upgraded Acadia to a Buy rating from Neutral, citing that a recent share price pullback is not tied to the company's fundamentals and maintaining a $29 price target in that note. In a separate note referenced in the same disclosure, BofA is recorded as having lowered its price target from $31 to $29 due to a pipeline review and an EU setback, while maintaining a Neutral rating.
That EU setback is further detailed in the disclosure: the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on Acadia's Marketing Authorization Application for trofinetide. The committee cited limited treatment effects and raised concerns about the scope of the study supporting the application. The company also announced a governance change, appointing Jonathan M. Poole to its board of directors and audit committee, with his term set to expire at the 2027 annual meeting of stockholders.
Taken together, the insider-share sale to meet tax obligations, the recent vesting of restricted stock units, valuation commentary from InvestingPro, analyst actions from BofA Securities, and the EMA's negative opinion on trofinetide are presented in the company's disclosures as contemporaneous items that investors may consider when assessing Acadia's position. The filings and analyst notes referenced here provide the factual basis for those considerations.